Studies have shown that in the early stages of AD, long before the appearance of clinical manifestations, the concentration of the 42aa β-amyloid peptide is lower,12, 13and that of the hyperphosphorylated tau protein is higher in the cerebrospinal fluid (CSF).14, 15. The gene discussed is MAPT; the disease is Alzheimer disease.